Bortei A. R., Zamorskii I. I.

EFFECT OF MELATONINERGIC DRUGS ON ANIMAL SURVIVAL IN ACUTE KIDNEY INJURY

---

Show/Download

About the author:

Bortei A. R., Zamorskii I. I.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

Despite the high prevalence and significant mortality rate associated with acute kidney injury, effective treatment and prevention strategies for this syndrome remain underdeveloped. At the same time, the use of pharmacological agents with nephroprotective properties is considered a promising approach to the pathogenetic correction of acute kidney injury. In this context, the hormone melatonin has attracted considerable attention due to its potent antioxidant and anti-inflammatory properties, and its nephroprotective effects have been demonstrated in a number of studies. Furthermore, some melatonin receptor agonists, in particular agomelatine, also reduce damage to nephrons in nephropathies of various etiologies. The aim of the study is to assess the nephroprotective efficacy of melatonin and agomelatine based on the survival rates of laboratory rats in two models of acute kidney injury (myoglobinuric and toxic) following pre-treatment with these drugs. The study was conducted on 57 sexually mature outbred male white rats weighing 160–200 g, divided into 7 groups (n=7–9): a control group, a model pathology group, and treatment groups receiving either agomelatine or the reference drug melatonin at a dose of 50 mg/kg intraperitoneally daily for 7 days prior and 7 days after to the induction of acute kidney injury. The myoglobinuric form of acute kidney injury was induced by intramuscular injection of a 50% osmotic glycerol solution at a dose of 10 mL/kg, whereas the toxic form of acute kidney injury was induced by intramuscular injection of gentamicin solution at a dose of 100 mg/kg. Statistical analysis of survival outcomes was performed using Fisher’s angular transformation (arcsine transformation). The study was conducted in accordance with ethical standards. According to the study results, both forms of acute kidney injury under investigation were associated with mortality among the experimental animals, while the lowest survival rate was observed in the toxic (gentamicin-induced) form – 62,5%. Administration of both melatonin and agomelatine improved survival in both models of acute kidney injury. Notably, higher survival rates were observed following the administration of agomelatine. Unlike melatonin, this medication completely prevented animal mortality in both forms of acute kidney injury.

Tags:

Bibliography:

1. Goyal A, Daneshpajouhnejad P, Hashmi MF, Bashir K. Acute kidney injury. Treasure Island (FL): StatPearls Publishing, 2025. Available from: https://www.ncbi.nlm.nih.gov/books/n/statpearls/article-17169/
2. Ostermann M, Lumlertgul N, Jeong R, See E, Joannidis M, James M. Acute kidney injury. Lancet. 2025;405(10474):241-256. DOI: https://doi.org/10.1016/s0140-6736(24)02385-7
3. Flowers NT, Croft J.B. Hospitalization discharge diagnoses for kidney disease - United States, 1980-2005. MMWR. 2008;57(12);309-312. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5712a1.htm
4. Gross C, Jonasson JM, Buchebner D, Agvall B. Prognosis and mortality within 90 days in community-acquired acute kidney injury in the Southwest of Sweden. BMC Nephrology. 2023;24:171. DOI: https://doi.org/10.1186/s12882-023-03221-2
5. Almazmomi MA, Esmat A, Naeem A. Acute kidney injury: definition, management, and promising therapeutic target. Cureus. 2023;15(12):e51228. DOI: https://doi.org/10.7759/cureus.51228
6. Zeleniuk VG, Zamorskii II, Gerush OV, Shchudrova TS, Goroshko OM, Zeleniuk AR. Comparative evaluation of renal, pleiotropic and myotropic effects of statins in rats. Fiziol. Zh. 2019;65(2):76-83. DOI: https://doi.org/10.15407/fz65.02.076
7. Hrenak J, Paulis L, Repova K, Aziriova S, Nagtegaal EJ, Reiter RJ, et al. Melatonin and renal protection: novel perspectives from animal experiments and human studies (review). Curr Pharm Des. 2015;21(7):936-49. DOI: https://doi.org/10.2174/1381612820666140929092929
8. Kusirisin P, Apaijai N, Noppakun K, Kuanprasert S, Chattipakorn SC, Chattipakorn N. Protective effects of melatonin on kidney function against contrast media-induced kidney damage in patients with chronic kidney disease: A prospective, randomized, double-blinded, placebo-controlled trial. J Pineal Res. 2025;77(1):e70031. DOI: https://doi.org/10.1111/jpi.70031
9. Markowska M, Niemczyk S, Romejko K. Melatonin treatment in kidney diseases. Cells. 2023;12(6):838. DOI: https://doi.org/10.3390/cells12060838
10. Dil E, Topcu A, Mercantepe T, Tumkaya L, Akyildiz K, Saral S, et al. Agomelatine on cisplatin-induced nephrotoxicity via oxidative stress and apoptosis. Naunyn Schmiedebergs Arch Pharmacol. 2023;396(10):2753-2764. DOI: https://doi.org/10.1007/s00210-023-02632-0
11. Aykora D, Bahar MR, Tanbek K, Öztürk DA, Karaca E, Sandal S, et al. An experimental insight into the role of agomelatine in renal ischemia/ reperfusion injury. J Biochem Mol Toxicol. 2024;38(12):e70090. DOI: https://doi.org/10.1002/jbt.70090
12. Karaman A, Diyarbakir B, Durur-Subasi I, Kose D, Özbek-Bilgin A, Topcu A, et al. A novel approach to contrast-induced nephrotoxicity: the melatonergic agent agomelatine. Br J Radiol. 2016;89(1061):20150716. DOI: https://doi.org/10.1259/bjr.20150716
13. Papp M, Gruca P, Boyer PA, Mocaër E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology. 2003;28(4):694-703. DOI: https://doi.org/10.1038/sj.npp.1300091
14. Singh AP, Junemann A, Muthuraman A, Jaggi AS, Singh N, Grover K, et al. Animal models of acute renal failure. Pharmacol Rep. 2012;64(1):31-44. DOI: https://doi.org/10.1016/s1734-1140(12)70728-4
15. Mahi-Birjand M, Yaghoubi S, Abdollahpour-Alitappeh M, Keshtkaran Z, Bagheri N, Pirouzi A, et al. Protective effects of pharmacological agents against aminoglycoside-induced nephrotoxicity: A systematic review. Expert Opin Drug Saf. 2020;19(2):167-186. DOI: https://doi.org/10.1080/14740338.2020.1712357
16. Drachuk VM, Zamorskyi II, Horoshko OM. Antyoksydantnyi potentsial ademetioninu za umov rozvytku hentamitsynovoi nefropatii. Aktualni problemy suchasnoi medytsyny: Visnyk Ukrainskoi medychnoi stomatolohichnoi akademii. 2020;20(1):8-12. DOI: https://doi.org/10.31718/2077-1096.20.1.8 [in Ukrainian].
17. Cabral BMI, Edding SN, Portocarrero JP, Lerma EV. Rhabdomyolysis. Dis Mon. 2020;66(8):101015. DOI: https://doi.org/10.1016/j.disamonth.2020.101015
18. Hsu CN, Tain YL. Melatonin as a redox modulator in developmental programming: Implications for cardiovascular-kidney-metabolic risk. Int J Mol Sci. 2026;27(5):2390. DOI: https://doi.org/10.3390/ijms27052390
19. Dudka Ye, Zamorskii I, Shchudrova T, Petriuk A, Kopchuk T, Drachuk V. Nephroprotective mechanisms, therapeutic potential and perspective on melatonin use for drug-induced nephropathy. Medical Science. 2021;25(107):163-169. Available from: https://discoveryjournals.org/medicalscience/current_issue/v25/n107/A20.htm
20. Savino R, Polito AN, Marsala G, Ventriglio A, Di Salvatore M, De Stefano MI, et al. Agomelatine: a potential multitarget compound for neurodevelopmental disorders. Brain Sci. 2023;13(5):734. DOI: https://doi.org/10.3390/brainsci13050734
21. Promsan S, Pengrattanachot N, Phengpol N, Sutthasupha P, Thongnak LO, Jaikumkao K, et al. Agomelatine mitigates kidney damage in obese insulin-resistant rats by inhibiting inflammation and necroptosis via the TNF-α/NF-ĸB/p-RIPK3 pathway. Int J Mol Sci. 2025;26(5):1940. DOI: https://doi.org/10.3390/ijms26051940

Publication of the article:

«Bulletin of problems biology and medicine», 2026 Issue 2, 181, 165-168 pages, index UDC [615.357:577.175.32].03:616.61-008.64

DOI:

10.29254/2077-4214-2026-2-181-165-168